Fibrinolytic nanocages dissolve clots in the tumor microenvironment, improving the distribution and therapeutic efficacy of anticancer drugs
Open Access
- 19 October 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Experimental & Molecular Medicine
- Vol. 53 (10), 1592-1601
- https://doi.org/10.1038/s12276-021-00688-7
Abstract
Fibrin, one of the components of the extracellular matrix (ECM), acts as a transport barrier within the core of tumors by constricting the blood vessels and forming clots, leading to poor intratumoral distribution of anticancer drugs. Our group previously developed a microplasmin-based thrombolytic ferritin nanocage that efficiently targets and dissolves clots without causing systemic fibrinolysis or disrupting hemostatic clots. We hypothesized that the thrombolytic nanocage-mediated degradation of fibrin clots in the tumor ECM can lead to enhanced intratumoral drug delivery, especially for nanosized anticancer drugs. Fibrin clot deposition worsens after surgery and chemotherapy, further hindering drug delivery. Moreover, the risk of venous thromboembolism (VTE) also increases. Here, we used thrombolytic nanocages with multivalent clot-targeting peptides and fibrin degradation enzymes, such as microplasmin, to dissolve fibrin in the tumor microenvironment and named them fibrinolytic nanocages (FNCs). These FNCs target tumor clots specifically and effectively. FNCs efficiently dissolve fibrin clots inside of the tumor vessels, suggesting that they can mitigate the risk of VTE in cancer patients. Coadministration of FNC and doxorubicin led to improved chemotherapeutic activity in a syngeneic mouse melanoma model. Furthermore, the FNCs increased the distribution of Doxil/doxorubicin nanoparticles within mouse tumors. These results suggest that fibrinolytic cotherapy might help improve the therapeutic efficacy of anticancer nanomedicines. Thus, microplasmin-based fibrinolytic nanocages are promising candidates for this strategy due to their hemostatic safety and ability to home in on the tumor.Keywords
Funding Information
- National Research Foundation of Korea (2020R1A2C1012164, 2018R1D1A3A03001116, 2014R1A5A2009242)
- Kyungpook National University (Development Project Research Fund, 2018)
This publication has 40 references indexed in Scilit:
- Discovery of an uncovered region in fibrin clots and its clinical significanceScientific Reports, 2013
- The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluationInternational Journal of Nanomedicine, 2013
- Guidelines for the Early Management of Patients With Acute Ischemic StrokeStroke, 2013
- Causes, consequences, and remedies for growth-induced solid stress in murine and human tumorsProceedings of the National Academy of Sciences of the United States of America, 2012
- Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal AdenocarcinomaCancer Cell, 2012
- Cancer as an overhealing wound: an old hypothesis revisitedNature Reviews Molecular Cell Biology, 2008
- Treatment of solid tumors and metastases by fibrinogen-targeted anticancer drug therapyMedical Hypotheses, 2007
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic TherapyScience, 2005
- Urokinase combination chemotherapy in small cell lung cancer. A phase II studyCancer, 1992
- The role of fibrin in tumor metastasisCancer and Metastasis Reviews, 1992